BACKGROUND AND AIMS: Kinetic modeling of hepatitis C virus (HCV) response to interferon (IFN)-based therapy provides insights into factors associated with treatment outcomes. HCV/human immunodeficiency virus (HIV)-co-infected patients show lower response rates vs. HCV-monoinfected patients. Reasons for this remain unclear. This study evaluated kinetic parameters and treatment responses in co-infected vs monoinfected patients. METHODS: Co-infected patients were randomized within a US multicenter trial (ACTG 5071) to receive pegylated-interferon (PEG-IFN) alfa-2a + ribavirin vs. IFN alfa-2a + ribavirin. Monoinfected controls were matched prospectively for treatment, genotype, age, sex, race, and histology. Quantitative HCV-RNA testing was performed at hours 0, 6, 12, 24, 48, and 72; days 7, 10, 14, 28, and 56; and weeks 12, 24, 48, and 72. RESULTS: Twelve HCV/HIV-co-infected and 15 HCV-monoinfected patients underwent viral kinetic sampling. Among HIV-positive patients the mean CD4(+) count was 325 cells/mm(3). Seventy-five percent of patients were genotype 1. The HCV-RNA level was undetectable at 72 weeks in 25% and 40% of co-infected and monoinfected patients, respectively. Phase 1/2 declines, free virus clearance rate, and infected hepatocyte death rate were not affected by co-infection status but differed by treatment. Efficiency (epsilon) > or = 90% at 60 hours was associated with viral clearance ( P = .02). Modeling with pooled parameters suggests baseline viral load is a key factor in time to response in this cohort. Predicted clearance time increased by 28% in co-infected patients. CONCLUSIONS: Co-infection status did not affect key kinetic parameters. Among kinetic parameters, efficiency was associated significantly with viral clearance. Co-infected patients may require longer treatment duration than monoinfected patients given their generally higher baseline viral loads.
RCT Entities:
BACKGROUND AND AIMS: Kinetic modeling of hepatitis C virus (HCV) response to interferon (IFN)-based therapy provides insights into factors associated with treatment outcomes. HCV/human immunodeficiency virus (HIV)-co-infectedpatients show lower response rates vs. HCV-monoinfected patients. Reasons for this remain unclear. This study evaluated kinetic parameters and treatment responses in co-infected vs monoinfected patients. METHODS: Co-infected patients were randomized within a US multicenter trial (ACTG 5071) to receive pegylated-interferon (PEG-IFN) alfa-2a + ribavirin vs. IFN alfa-2a + ribavirin. Monoinfected controls were matched prospectively for treatment, genotype, age, sex, race, and histology. Quantitative HCV-RNA testing was performed at hours 0, 6, 12, 24, 48, and 72; days 7, 10, 14, 28, and 56; and weeks 12, 24, 48, and 72. RESULTS: Twelve HCV/HIV-co-infected and 15 HCV-monoinfected patients underwent viral kinetic sampling. Among HIV-positivepatients the mean CD4(+) count was 325 cells/mm(3). Seventy-five percent of patients were genotype 1. The HCV-RNA level was undetectable at 72 weeks in 25% and 40% of co-infected and monoinfected patients, respectively. Phase 1/2 declines, free virus clearance rate, and infected hepatocyte death rate were not affected by co-infection status but differed by treatment. Efficiency (epsilon) > or = 90% at 60 hours was associated with viral clearance ( P = .02). Modeling with pooled parameters suggests baseline viral load is a key factor in time to response in this cohort. Predicted clearance time increased by 28% in co-infected patients. CONCLUSIONS: Co-infection status did not affect key kinetic parameters. Among kinetic parameters, efficiency was associated significantly with viral clearance. Co-infected patients may require longer treatment duration than monoinfected patients given their generally higher baseline viral loads.
Authors: J M Matthews-Greer; G C Caldito; S D Adley; R Willis; A C Mire; R M Jamison; K L McRae; J W King; W L Chang Journal: Clin Diagn Lab Immunol Date: 2001-07
Authors: M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht Journal: Lancet Date: 2001-09-22 Impact factor: 79.321
Authors: A M Roque Afonso; J Jiang; F Penin; C Tareau; D Samuel; M A Petit; H Bismuth; E Dussaix; C Féray Journal: J Virol Date: 1999-11 Impact factor: 5.103
Authors: Jennifer E Layden-Almer; Ruy M Ribeiro; Thelma Wiley; Alan S Perelson; Thomas J Layden Journal: Hepatology Date: 2003-06 Impact factor: 17.425
Authors: Kimberly A Powers; Narendra M Dixit; Ruy M Ribeiro; Preeti Golia; Andrew H Talal; Alan S Perelson Journal: Semin Liver Dis Date: 2003 Impact factor: 6.115
Authors: Francesca J Torriani; Ruy M Ribeiro; Tari L Gilbert; Uschi M Schrenk; Marietta Clauson; DeeDee M Pacheco; Alan S Perelson Journal: J Infect Dis Date: 2003-11-13 Impact factor: 5.226
Authors: G V Matthews; S T Pham; M Hellard; J Grebely; L Zhang; A Oon; P Marks; I van Beek; W Rawlinson; J M Kaldor; A Lloyd; G J Dore; P A White Journal: Clin Infect Dis Date: 2011-01-31 Impact factor: 9.079
Authors: Kenneth E Sherman; Jeremie Guedj; Mohamed Tarek Shata; Jason T Blackard; Susan D Rouster; Mario Castro; Judith Feinberg; Richard K Sterling; Zachary Goodman; Bruce J Aronow; Alan S Perelson Journal: Sci Transl Med Date: 2014-07-23 Impact factor: 17.956
Authors: Neumann U Avidan; Deborah Goldstein; Lynn Rozenberg; Mary McLaughlin; Peter Ferenci; Henry Masur; Maria Buti; Anthony S Fauci; Michael A Polis; Shyam Kottilil Journal: J Acquir Immune Defic Syndr Date: 2009-12-01 Impact factor: 3.731